GlobeNewswire by notified

Immunicum kommer under januari månad att delta i följande investerarmöten och branschkonferenser

Dela

Pressmedelande 

Stockholm, 3 januari 2022

Immunicum kommer under januari månad att delta i följande investerarmöten och branschkonferenser

Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på svårbehandlade solida tumörer och förebyggande av canceråterfall, tillkännagav idag sitt deltagande i följande investerarmöten och branschkonferenser under januari. 

  • H.C. Wainwright Bioconnect Virtual Conference, 10 – 13 januari, 2022
    • Erik Manting, vd, kommer att hålla en företagspresentation samt delta i digitala investerarmöten (one-on-ones) under konferensen.
  • Stern IR digitala kundmöten, 10 – 13 januari, 2022
    • Erik Manting kommer att delta i investerarmöten (one-on-ones) under evenemanget.
  • Allogeneic Cell Therapies Summit Europe, digitalt möte, 18 – 20 januari, 2022
  • Satwinder Kaur-Singh, forskningsdirektör på Immunicum, kommer att presentera "Understanding and Applying Allogeneic Dendritic Cell Biology" i en session som syftar till att belysa viktiga överväganden för att undvika efterföljande komplikationer, vid utformning av cancerterapier.
    Torsdagen den 20 januari kl. 12:30 CET.
  • Redeye Tema: Fight Cancer seminarium – utblick 2022, 20 januari, 2022
    • Erik Manting kommer att presentera Immunicum och besvara frågor i en session modererad av Redeyes forskningsanalytiker kl. 13.05 – 13.25 CET.
      Redeye Fight Cancer seminarium är ett årligen återkommande event där Redeye bjuder in några av de ledande nordiska företagen inom området för att dessa ska ge uppdateringar om sina prioriteringar, utmaningar och förväntade framsteg under 2022. Seminariet sänds och är tillgängligt för alla Redeye-medlemmar via denna nk.

FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA:

Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com

INVESTOR RELATIONS

Brendan Payne
Stern Investor Relations
Telephone: +1 212-698-8695
E-mail: brendan.payne@sternir.com

För Sverige:

Kristina Windrup Olander
Spikinc AB
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com

PRESSFRÅGOR

Eva Mulder & Sophia Hergenhan
Trophic Communications
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu

OM IMMUNICUM AB (PUBL)


Immunicum är ett bioteknikbolag som fokuserar på svårbehandlade etablerade tumörer och tumöråterfall, två viktiga utmaningar inom dagens onkologi. Vi utnyttjar vår expertis inom allogen dendritcells-biologi för att utveckla en avancerad klinisk pipeline av nya off-the-shelf produkter för solida och blodburna tumörer. Baserat i Sverige och Nederländerna, Immunicum är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Bombardier Announces Firm Order for the First Challenger 3500 Business Jet based in Europe for Charter Operations with Air Corporate SRL8.8.2022 14:00:00 CEST | Press release

Italian-based Air Corporate SRL to be the first European operator to offer the Challenger 3500 business jet for charter services, which will join the company’s fleet of aircraft With its innovative technology, redesigned cabin and sustainably minded features, the Challenger 3500 business jet is ideally suited for the European charter market MONTREAL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bombardier today announced the sale of its industry-leading Challenger3500 business jet to Italian-based operator, Air Corporate SRL. This will be the first company to offer the aircraft for charter in Europe. Introduced in 2021, the new Challenger 3500 aircraft offers a unique blend of performance, advantageous operating costs, ultimate cabin experience and smooth ride, making it an ideal choice for the European charter market. And with its redesigned interior with intelligent and sustainably minded cabin features, the Challenger 3500 aircraft is elegantly crafted to combine comfort with function, fully e

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme8.8.2022 11:45:00 CEST | Press release

Company Announcement No. 49/2022 Copenhagen, 8 Aug 2022 Transactions in connection with share buy-back programme On 19 May 2022, Scandinavian Tobacco Group A/S announced that the share buy-back programme that was initiated 9 March 2022 was increased to an aggregated value of up to DKK 1,000 million. The purpose of the programme is to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 35/2022. The share buy-back programme will end no later than 28 February 2023. The fo

Maha Energy AB enters into a Farmout Agreement with Mafraq Energy LLC for Block 70 in Oman8.8.2022 11:00:00 CEST | Press release

Maha Energy AB (publ) (“Maha” or the “Company”), through its wholly owned subsidiary Maha Energy (Oman) Ltd., has entered into an Agreement with Mafraq Energy LLC for Maha to reduce the Participating Interest in the Block 70 Exploration and Production Sharing Agreement (“EPSA”) in Oman from 100% to 65%. Maha will continue to be the Operator of the Block. The Agreement is subject to Government approval in Oman. Maha has decided to reduce its working interest in the onshore oil-bearing Block 70 in Oman by bringing in a strategic Omani partner. The Agreement requires Mafraq Energy LLC to reimburse Maha for their prorated share of all past costs including the signature bonus. Mafraq Energy LLC will also be required to pay their share of all future expenditures on Block 70. Jonas Lindvall, Maha’s CEO said: “We are delighted to have Mafraq Energy LLC join us on Block 70. Mafraq Energy LLC brings extensive experience of the Mafraq field and the surrounding areas in Oman. The fact that Mafraq